Home › Atopic Dermatitis (Eczema) › NCT05858619

Molecular Signatures of Cutaneous Dupilumab Response

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. 18 years of age or older
2. atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7

Exclusion Criteria:

1. Known pregnancy
2. Known immunodeficiencies
3. Known parasitic infection -

About the study

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

What is being tested

• Dupilumab (drug)

Sponsor: University of California, San Francisco · Participants: 15 · Started: Feb 1, 2023

Contact the study team

• Jeffrey Cheng, MD, PhD · Phone: 415 575 0524

Official record on ClinicalTrials.gov — NCT05858619

Locations in the U.S.

Conditions

• Atopic Dermatitis (Eczema)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.